Abbott Laboratories
Change company
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
IE
US
US
US
US
US
IN
US
US
US
US
US
US
US
US
US
US
US
US
US
AU
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
JP
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
BM
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
Track Abbott Laboratories in real time with a live news feed covering Abbott Laboratories stock news, official press releases, company announcements, and an archive of historical Abbott Laboratories news. ...more
Loading news...
Loading more...
2:15 PM | Saturday | Oct 10, 2026
Sign in to download news snippet
Abbott has grown its earnings per share at a nearly 10% compound annual rate over the past decade. Its stock price could more than double by 2036 using a more conservative 8% growth rate.
Read full articleNo data available for this time period.
Change the time range to see results.
Abbott has grown its earnings per share at a nearly 10% compound annual rate over the past decade. Its stock price could more than double by 2036 using a more conservative 8% growth rate.
Read full article
Abbott has grown its earnings per share at a nearly 10% compound annual rate over the past decade. Its stock price could more than double by 2036 using a more conservative 8% growth rate.
Read full article
Oncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.
Read full article
These companies might bend during a downturn, but they won't break.
Read full article
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read full article
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Read full article
New powder combines 30 grams of high‑quality protein to help build muscle tissue,† 5 grams of creatine monohydrate to support muscle recovery‡* and 3 grams of calcium HMB (beta-hydroxy-beta-methylbutyrate) to help preserve muscle Ensure Max Protein 3-in-1 formula provides muscle support in a single daily serving to support muscle health goals—and is available in chocolate and vanilla at major U.S. retailers Muscle-supporting ingredients like creatine and HMB are moving beyond the gym and into mainstream wellness routines as more adults prioritize strength and fitness ABBOTT PARK, Ill., Oct. 7, 2026 /PRNewswire/ -- Muscle support just got simpler.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Read full article
Stocks shattered records again Tuesday while oil surged, gold hit new highs, and crypto swung wildly, setting the stage for a fresh wave of analyst moves on names like Marvell, Intuitive Surgical, and NetApp that could reshape portfolios heading into the rest of the week.
Read full article
Both Medtronic and Abbott have dropped in 2026, and those declines reshuffled the math on yield, valuation, and long-term growth in ways that push retirement investors toward a clear but maybe surprising choice.
Read full article
For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App Rising PAP can signal worsening heart failure weeks before patients experience symptoms New capabilities help patients take a more active role in their care and stay connected to their care teams between doctor visits ABBOTT PARK, Ill., Oct. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, today announced U.
S. Food and Drug Administration (FDA) approval for updates to the CardioMEMS HF System that enable new patient-facing capabilities through the CardioGuide HF App.
No data available for this time period.
Change the time range to see results.